103 related articles for article (PubMed ID: 8850107)
1. [Economical treatment of heart failure].
Sonntag F
Med Klin (Munich); 1996 Feb; 91(2):111. PubMed ID: 8850107
[No Abstract] [Full Text] [Related]
2. [Cost effectiveness of captopril after myocardial infarct; comment].
Szucs T; Berger K; Schulte-Hillen J; Kleber FX
Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis and clinical practice.
Rector TS; Francis GS
J Am Coll Cardiol; 1995 Oct; 26(4):920-1. PubMed ID: 7560618
[No Abstract] [Full Text] [Related]
4. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
[TBL] [Abstract][Full Text] [Related]
5. Economic aspects of captopril treatment.
Tsevat J; Pfeffer MA; Goldman L; Lee TH
Eur Heart J; 1997 Jan; 18(1):165. PubMed ID: 9049528
[No Abstract] [Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. [Captopril in the treatment of heart failure].
Kékes E
Acta Pharm Hung; 1997 Jul; 67(4):155-63. PubMed ID: 9289944
[TBL] [Abstract][Full Text] [Related]
8. The impact of angiotensin-converting enzyme inhibitors on managed care: economic, clinical, and humanistic outcomes.
Reeder CE; Gourley GA; Wurtzbacher JD; Reed P
Am J Manag Care; 2000 Feb; 6(3 Suppl):S112-28, quiz S129-31. PubMed ID: 10977441
[TBL] [Abstract][Full Text] [Related]
9. Zofenopril after anterior myocardial infarction.
Chaudhry GM; Haneef N
N Engl J Med; 1995 Jun; 332(25):1716. PubMed ID: 7760878
[No Abstract] [Full Text] [Related]
10. Valsartan, captopril, or both in myocardial infarction.
McAnulty JH
N Engl J Med; 2004 Feb; 350(9):943-5; author reply 943-5. PubMed ID: 14985495
[No Abstract] [Full Text] [Related]
11. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
Dickstein K
Am Heart J; 2003 May; 145(5):754-7. PubMed ID: 12766730
[No Abstract] [Full Text] [Related]
12. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis.
Choudhry NK; Avorn J; Antman EM; Schneeweiss S; Shrank WH
Health Aff (Millwood); 2007; 26(1):186-94. PubMed ID: 17211028
[TBL] [Abstract][Full Text] [Related]
13. [Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
MMW Fortschr Med; 2003 Oct; 145(43):51. PubMed ID: 14664222
[No Abstract] [Full Text] [Related]
14. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
15. [The treatment of asymptomatic ventricular dysfunction with angiotensin-converting enzyme inhibitors].
de Teresa E
Rev Esp Cardiol; 1994 Oct; 47(10):643-7. PubMed ID: 7991916
[No Abstract] [Full Text] [Related]
16. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure.
Szucs TD
Am J Hypertens; 1997 Oct; 10(10 Pt 2):272S-279S. PubMed ID: 9366284
[TBL] [Abstract][Full Text] [Related]
17. Issues concerning the use of angiotensin-converting enzyme inhibitors in the treatment of heart failure and myocardial infarction.
Poole-Wilson PA
Arch Mal Coeur Vaiss; 1994 Jun; 87 Spec No 2():35-8. PubMed ID: 7864720
[No Abstract] [Full Text] [Related]
18. Erythropoietin levels in heart failure after an acute myocardial infarction: determinants, prognostic value, and the effects of captopril versus losartan.
Belonje AM; Westenbrink BD; Voors AA; von Haehling S; Ponikowski P; Anker SD; van Veldhuisen DJ; Dickstein K
Am Heart J; 2009 Jan; 157(1):91-6. PubMed ID: 19081402
[TBL] [Abstract][Full Text] [Related]
19. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
[No Abstract] [Full Text] [Related]
20. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
